| Author (Corporate) | European Medicines Agency |
|---|---|
| Series Title | Press Release |
| Series Details | EMA/337406/2012 (25.5.12) |
| Publication Date | 25/05/2012 |
| Content Type | News |
|
The European Medicines Agency, on 25 May 2012, recommended updating the product information for the blood thinner Pradaxa, to give clearer guidance to doctors and patients on how to reduce and manage the risk of bleeding associated with the anticoagulant medicine. Pradaxa is an anticoagulant (a medicine that prevents the blood from clotting). It is prescribed to adults who have had hip or knee replacement surgery to prevent venous thromboembolic events and also to patients with non-valvular atrial fibrillation to prevent stroke and systemic embolism. |
|
| Source Link | Link to Main Source http://www.emea.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2012/05/news_detail_001518.jsp&mid=WC0b01ac058004d5c1 |
| Related Links |
|
| Subject Categories | Health |
| Countries / Regions | Europe |
